Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. , and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Completed the acquisition of Ambry Genetics on February 3, 2025. Disclosed a collaboration with Illumina combining its AI technologies with Tempus’ comprehensive multimodal data platform to ...

said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year. During the first ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The company reports a first-quarter adjusted loss of 24 cents per share, beating analyst ...